HC Wainwright Reiterates Rating on NVCT $NVCT

Written by Podchat · Published · Updated

Editorial illustration for Nuvectis Pharma, Inc. (NVCT)

Key Points

  • HC Wainwright now rates Nuvectis Pharma, Inc. ($NVCT) "buy" with a $13 target.
  • HC Wainwright's $13 price target implies 21.21% upside from Nuvectis Pharma, Inc.'s ($NVCT) current $10.72 share price.
  • The Street's average $NVCT price target is $34.20 (Strong Buy).
  • $NVCT last traded around $10.72.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

HC Wainwright reiterated its rating on Nuvectis Pharma, Inc. ($NVCT) to a "buy" rating in a recent research note and set a price target of $13, a 21.21% upside from the current price.

Nuvectis Pharma, Inc. Stock Down 54.8%

Shares of Nuvectis Pharma, Inc. ($NVCT) traded around $10.72 on Saturday, down 54.8% for the day.

Last price$10.72
Market cap$742M
Forward P/E-23.68
Beta-0.26
52-week low$5.55
52-week high$29.27
50-day MA$20.80
200-day MA$11.65
Current ratio1.68
Quick ratio1.67

Nuvectis Pharma, Inc. Earnings

EPS (ttm)-$1.26
Revenue (ttm)—
Net margin0%
Return on equity-214.58%
Next earningsNov 3, 2026

Analysts Set New Price Targets

ConsensusStrong Buy
Average target$34.20
High target$39
Low target$30
Analysts covering5

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

ExchangeNasdaqCM
SectorHealthcare
IndustryBiotechnology
HeadquartersFort Lee, NJ
CEOMr. Ron Bentsur M.B.A.
Employees16
Websitehttps://www.nuvectis.com

Get Nuvectis Pharma, Inc. alerts

New 13F filings, insider trades, and analyst moves on $NVCT, sent to your inbox. Free, and you can unsubscribe anytime.

Related Filing Alerts

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.